Indivior rebuffs complaint from 35 US states

Pharmaceutical company Indivior once again rebuffed legal claims laid against it on Tuesday, after a number of states in the US filed a joint civil complaint over its conduct with the Suboxone product.

The FTSE 250 firm had initially warned the market of the impending complaint, from 35 states and the District of Columbia, on Friday.

On Tuesday it responded to a redacted copy of the complaint.

“[The complaint] alleges, among other things, that Indivior, along with other defendants, switched Suboxone treatment from a tablet to a film formulation in order to prevent or delay the introduction of generic alternatives,” Indivior’s board said in the statement.

“The company continues to take these allegations seriously, intends to defend this and other related actions, and will continue to cooperate with the relevant US government agencies in their investigations of the company.”

Indivior said it is assessing the matter, the Federal Trade Commission and Department of Justice investigations, the private class action and other litigations to “determine the implications to the provision on the company's balance sheet for such matters”.